M3, Inc.
M3, Inc. Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [IFRS] (Consolidated)
For the second quarter (interim) of the fiscal year ending March 2027, revenue was 181,853 million yen, operating income was 36,335 million yen, and interim profit was 22,623 million yen. Year-over-year, revenue increased by 6.4%, operating income increased by 1.0%, while interim profit decreased by 10.7%. By segment, the Medical Platform performed well, while Site Solutions saw margin pressure due to lower unit prices and upfront investments. Full-year dividend forecast is TBD. An earnings presentation is scheduled.
Key Figures
- Revenue: 181,853 million yen
- Operating Income: 36,335 million yen
- Interim Profit: 22,623 million yen
AI要約
Performance Overview
M3's consolidated results for the second quarter (interim) of the fiscal year ending March 2027 showed revenue of 181,853 million yen, an increase of 6.4% year-over-year. Operating income was 36,335 million yen, up 1.0%, pre-tax profit was 36,620 million yen, and interim profit was 22,623 million yen, declining from the prior year. By segment, Medical Platform and overseas operations remained solid, while Site Solutions faced profit compression due to the impact of medical fee revisions and new investments. Supplemental materials to the financial summary will be published on the same day, and an earnings presentation will be held.
Shareholder Returns and Outlook
The full-year dividend forecast for the fiscal year ending March 2027 is TBD. The company will determine future shareholder distributions based on funding needs and cash flow. The number of treasury shares at the interim period-end has not increased, and shareholder returns will continue to be monitored. The financial summary explicitly states there are no revisions to the full-year earnings guidance for fiscal 2027.
M3, Inc.
Company overview · Stock price · Financial data · All IR
